Grant access via the NHS to Lecanemab & Donanemab on prescription
Open for signatures until 24 February 2027.
627 signatures
- More than 250 signatures: considered by the Petitions CommitteeReached
- More than 10,000 signatures: considered for a debate in the SeneddNot reached
I have been involved in Alzheimer’s research for 15 years and would like the opportunity to access drugs that could delay the symptoms of Alzheimer’s, not just for myself but for all suffering with dementia.
More details
Lecanemab & Donanemab are drugs licensed by the UK’s MHRA, for the treatment of mild Alzheimer's symptoms. It is clinically proven to slow the progression of Alzheimer's disease. Clinical trials showed they slowed the onset of people with early Alzheimer’s Disease.
Nearly 1 million people live with Dementia in the UK, costing the economy an estimated £42 million per year.
Familial Alzheimer’s disease accounts for less than 1% of all Dementia cases. People who carry that genetic mutation will develop Alzheimer’s Disease symptoms before the age of 65.
Signatures by constituency
The Senedd's petitions website lists 581 of the 627 signatures under a Senedd constituency.
| Constituency | Signatures |
|---|---|
| Blaenau Gwent Caerffili Rhymni | 420 |
| Casnewydd Islwyn | 73 |
| Pontypridd Cynon Merthyr | 46 |
| Caerdydd Ffynnon Taf | 13 |
| Caerdydd Penarth | 6 |
| Afan Ogwr Rhondda | 5 |